Avanos Medical, Inc. (NYSE:AVNS – Get Free Report) was the target of a significant increase in short interest in August. As of August 15th, there was short interest totalling 730,900 shares, an increase of 5.4% from the July 31st total of 693,200 shares. Currently, 1.6% of the company’s shares are short sold. Based on an average daily trading volume, of 211,400 shares, the days-to-cover ratio is presently 3.5 days.
Analyst Ratings Changes
Several equities analysts recently issued reports on the stock. JMP Securities reissued a “market perform” rating on shares of Avanos Medical in a research note on Tuesday, May 7th. StockNews.com raised Avanos Medical from a “hold” rating to a “buy” rating in a research note on Saturday, May 11th.
Read Our Latest Stock Analysis on Avanos Medical
Avanos Medical Trading Up 0.3 %
Avanos Medical (NYSE:AVNS – Get Free Report) last released its earnings results on Wednesday, July 31st. The company reported $0.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.29 by $0.05. Avanos Medical had a net margin of 1.13% and a return on equity of 4.48%. The business had revenue of $171.70 million for the quarter, compared to analysts’ expectations of $170.67 million. During the same period last year, the company earned $0.24 earnings per share. The company’s quarterly revenue was up 1.4% on a year-over-year basis. On average, equities analysts predict that Avanos Medical will post 1.39 EPS for the current year.
Institutional Trading of Avanos Medical
A number of institutional investors and hedge funds have recently made changes to their positions in the company. Russell Investments Group Ltd. raised its holdings in shares of Avanos Medical by 19.8% in the 4th quarter. Russell Investments Group Ltd. now owns 62,420 shares of the company’s stock worth $1,400,000 after purchasing an additional 10,316 shares during the period. Natixis Advisors L.P. purchased a new position in Avanos Medical in the fourth quarter valued at approximately $317,000. Gladius Capital Management LP lifted its position in Avanos Medical by 63.0% during the fourth quarter. Gladius Capital Management LP now owns 2,416 shares of the company’s stock valued at $54,000 after buying an additional 934 shares in the last quarter. Norges Bank purchased a new stake in Avanos Medical during the fourth quarter worth approximately $7,016,000. Finally, Associated Banc Corp increased its position in shares of Avanos Medical by 114.5% in the fourth quarter. Associated Banc Corp now owns 27,904 shares of the company’s stock worth $626,000 after acquiring an additional 14,894 shares in the last quarter. 95.17% of the stock is currently owned by institutional investors and hedge funds.
Avanos Medical Company Profile
Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.
Featured Articles
- Five stocks we like better than Avanos Medical
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Autodesk Stock: Analysts’ Top AI Pick You Shouldn’t Overlook
- Market Cap Calculator: How to Calculate Market Cap
- Hidden Opportunities in Li Auto’s Tough Quarter You Can’t Miss
- What is Short Interest? How to Use It
- Don’t Overlook Campbell Soup: Here’s What Could Drive Its Stock
Receive News & Ratings for Avanos Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avanos Medical and related companies with MarketBeat.com's FREE daily email newsletter.